Clodia Osipo, Ph.D.
Clodia Osipo, Ph.D. 
Assistant Professor
Phone: 708-327-3177 Fax: 708-327-2245 Email: cosipo@lumc.edu
Dr. Clodia Osipo received her Ph.D. in Molecular and Cellular Biochemistry from Loyola University in 2002 while working under Dr. Allen Frankfater. Thereafter, Dr. Osipo did her post-doctoral fellowship at the Robert H. Lurie Comprehensive Cancer Center of the Feinberg School of Medicine at Northwestern University. Dr. V. Craig Jordan, the principal developer of adjuvant tamoxifen therapy for estrogen receptor positive breast cancer, was her mentor. Dr. Osipo�s research under Dr. Jordan focused on investigating the role of HER2/neu, the second member of the epidermal growth factor receptor family, in breast tumors that had acquired resistance to tamoxifen in vivo. During this time, Dr. Osipo has published numerous articles, reviews, and book chapters on tamoxifen and other selective estrogen receptor modulators and downregulators. Dr. Osipo joined Dr. Lucio Miele's breast cancer program as an Assistant professor in September of 2005.
Dr. Osipo's research focuses on:
1.) Elucidating the role of the IGF-1 signaling pathway in breast tumors that do and not respond to trastuzumab (Herceptin�).
2.) Investigating crosstalk between HER2/neu, IGF-1R, and Notch in breast cancer.
3.) Identifying novel therapeutic targets in breast cancer for the deveetreatment modalities.
4.) Improving approved therapies for breast cancer by identifying combination approaches
Selected Publications:
Osipo C, Liu H, Meeke K, Jordan VC: The Consequences of Exhaustive Antiestrogen Therapy in Breast Cancer: Estrogen-induced Tumor Cell Death. Experimental Biology and Medicine, Sep;229(8):722-31.
Review (2004) Lewis JS, Osipo C, Meeke K, Jordan VC: Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal. J Steroid Biochem Mol Biol., Feb;94(1-3):131-41 (2005)
Osipo C, Gajdos C, Cheng D, Jordan VC: Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy. J Steroid Biochem Mol Biol., Feb;93(2-5):249-56 (2005)
Osipo C, Meeke K, Liu H, Cheng D, Lim S, Weichel A, Jordan VC: Trastuzumab therapy for tamoxifen-stimulated endometrial cancer. Cancer Res.,Sep 15;65(18):8504-13 (2005)
Jordan VC, Lewis JS, Osipo C, Cheng D: The apoptotic action of estrogen following exhaustive antihormonal therapy: A new clinical treatment strategy. Breast, Sep 29; (2005)
Levenson AS, Thurn KE, Simons LA, Veliceasa D, Jarrett J, Osipo C, Jordan VC, Volpert OV, Satcher RL Jr, Gartenhaus RB: MCT-1 oncogene contributes to increased in vivo tumorigenicity of MCF7 cells by promotion of angiogenesis and inhibition of apoptosis. Cancer Res., Dec 1;65(23):10651-6 (2005)
Lewis JS, Meeke K, Osipo C, Ross EA, Kidawi N, Li T, Bell E, Chandel NS, Jordan VC: Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J Natl Cancer Inst., Dec 7;97(23):1746-59 (2005)
O'Regan R, Osipo C, Ariazi E, Lee ES, Meeke K, Morris C, Bertucci A, Sarker MAB, Grigg R, Jordan VC: Development and Therapeutic Options for the Treatment of Raloxifene-Stimulated Breast Cancer in Athymic Mice. Clin Cancer Res., April 1;12(7):2255-2263 (2006)
Liu H, Cheng D, Weichel AK, Osipo C, Wing LK, Chen B, Louis TE, Jordan VC: Cooperative effect of gefitinib and fumitremorgin c on cell growth and chemosensitivity in estrogen receptor alpha negative fulvestrant-resistant MCF-7 cells. Int J Oncol., Nov;29(5):1237-46 (2006)
Osipo C, Meeke K, Cheng D, Weichel A, Bertucci A, Liu H, Jordan VC: Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer. Int J Oncol., Feb;30(2):509-20 (2007)
Paunesku T, Vogt S, Lai B, Maser J, Stojicevic N, Thurn KT, Osipo C, Liu H, Legnini D, Wang Z, Lee C, Woloschak GE: Intracellular Distribution of TiO(2)-DNA Oligonucleotide Nanoconjugates Directed to Nucleolus and Mitochondria Indicates Sequence Specificity. Nano Lett., Feb 3; [Epub ahead of print] (2007)
Osipo C, Golde TE, Osborne BA, Miele LA.Off the beaten pathway: the complex cross talk between Notch and NF-kappaB. Lab Invest. 2008 Jan;88(1):11-7. Epub 2007 Dec 3.
Osipo C, Patel P, Rizzo P, Clementz AG, Hao L, Golde TE, Miele L. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor. Oncogene. 2008 Aug 28;27(37):5019-32. Epub 2008 May 12.
Rizzo P, Miao H, D'Souza G, Osipo C, Song LL, Yun J, Zhao H, Mascarenhas J, Wyatt D, Antico G, Hao L, Yao K, Rajan P, Hicks C, Siziopikou K, Selvaggi S, Bashir A, Bhandari D, Marchese A, Lendahl U, Qin JZ, Tonetti DA, Albain K, Nickoloff BJ, Miele L. Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Res. 2008 Jul 1;68(13):5226-35.
Rizzo P, Osipo C, Foreman K, Golde T, Osborne B, Miele L. Rational targeting of Notch signaling in cancer. Oncogene. 2008 Sep 1;27(38):5124-31. Review.
Rizzo P, Osipo C, Pannutia A, Golde T, Osborne B, Miele L. Targeting Notch signaling cross-talk with estrogen receptor and ErbB2 in breast cancer. Adv Enzyme Regul. 2009 Jan 20. [Epub ahead of print]